Skip Navigation

JNCI Journal of the National Cancer Institute 2000 92(18):1535-1536; doi:10.1093/jnci/92.18.1535
© 2000 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Pirnia, F.
Right arrow Articles by Borner, M. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pirnia, F.
Right arrow Articles by Borner, M. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 92, No. 18, 1535-1536, September 20, 2000
© 2000 Oxford University Press

CORRESPONDENCE

Uncertain Identity of Doxorubicin-Resistant MCF-7 Cell Lines Expressing Mutated p53

Farzaneh Pirnia, Madlaina Breuleux, Erasmus Schneider, Manfred Hochmeister, Susan E. Bates, Andreas Marti, Michel A. Hotz, Daniel C. Betticher, Markus M. Borner

Affiliations of authors: F. Pirnia, M. Breuleux, D. C. Betticher, M. M. Borner (Institute of Medical Oncology), M. A. Hotz (Department of Ear, Nose and Throat Surgery), Inselspital, Bern, Switzerland; M. Hochmeister (Department of Forensic Medicine), A. Marti (Department for Clinical Research), University of Bern; E. Schneider, Division of Molecular Medicine, Wadsworth Center, New York State Department of Health, Albany, NY; S. E. Bates, Medicine Branch, National Cancer Institute, Bethesda, MD.

Correspondence to: Markus M. Borner, M.D., Institute of Medical Oncology, Inselspital, 3010 Bern, Switzerland (e-mail: mborner@insel.ch).

The doxorubicin (ADR)-selected human breast cancer cell line (MCF-7/ADR-RES) has been a useful model for a multidrug-resistant subline in cancer research. However, a recent letter to the Journal has alerted the scientific community about the finding that MCF-7/ADR-RES is not a MCF-7-derived cell line. This report led to a change of nomenclature from MCF-7/ADR-RES to NCI/ADR-RES (1).

. . . [Full Text of this Article]

REFERENCES


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cancer Res.Home page
S. Kasibhatla, V. Baichwal, S. X. Cai, B. Roth, I. Skvortsova, S. Skvortsov, P. Lukas, N. M. English, N. Sirisoma, J. Drewe, et al.
MPC-6827: A Small-Molecule Inhibitor of Microtubule Formation That Is Not a Substrate for Multidrug Resistance Pumps
Cancer Res., June 15, 2007; 67(12): 5865 - 5871.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
E. Norris-Cervetto, R. Callaghan, F. M. Platt, R. A. Dwek, and T. D. Butters
Inhibition of Glucosylceramide Synthase Does Not Reverse Drug Resistance in Cancer Cells
J. Biol. Chem., September 24, 2004; 279(39): 40412 - 40418.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
F. Pirnia and M. M. Borner
RESPONSE: Multidrug-Resistant MCF-7 Cells: An Identity Crisis?
J Natl Cancer Inst, November 6, 2002; 94(21): 1654 - 1654.
[Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
K. Mehta, E. Devarajan, J. Chen, A. Multani, and S. Pathak
Multidrug-Resistant MCF-7 Cells: An Identity Crisis?
J Natl Cancer Inst, November 6, 2002; 94(21): 1652 - 1654.
[Full Text] [PDF]